Work

Familial adenomatous polyposis-associated stage IIIB colon cancer with ultrahigh tumor mutational burden and POLE p.P286R mutation: a case report

Year: 2026
Type: article
Study design: Case Report
Abstract: Background Pathogenic POLE proofreading-domain variants can accompany ultrahigh tumor mutational burden (TMB) in microsatellite-stable (MSS) colorectal cancer. Their role in postoperative treatment of familial adenomatous polyposis (FAP)-associated cancer remains uncertain. Case summary A man in his early forties with extensive colorectal polyposis underwent subtotal colectomy for pT3N1b, clinically M0, stage IIIB ascending colon adenocarcinoma. Paired tumor–blood sequencing identified pathogenic germline APC p.R232*, tumor POLE p.P286R (variant allele fraction 19.75%; not detected in blood), MSS status, and panel-derived TMB of 333.57 mutations/Mb. Initial MMR immunohistochemistry was reported as pan-loss; repeat staining was interpreted as proficient MMR. Incomplete documentation of internal controls prevents confirmation of the cause of this discordance. After declining chemotherapy, the patient received five postoperative doses of sintilimab from February 14 to May 15, 2025. CEA had normalized before the first dose; CA72–4 had also declined after surgery. No recurrence was reported on available surveillance through September 14, 2026. Conclusion The case illustrates the value and limitations of integrated pathological and molecular assessment in FAP-associated cancer. The absence of measurable disease at treatment initiation, postoperative marker decline, and limited follow-up prevent attribution of the outcome to sintilimab. This observation cannot establish cure or the efficacy of adjuvant PD-1 monotherapy.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7225880240
FWCI:
Cites: 17
Cited by:
Related to: 10